Janet focuses on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Her clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. She is noted for her in-depth knowledge of patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. She has Ph.D. in Biological Chemistry from University of California, Los Angeles, and an M.S. in Molecular Biology and Protein Chemistry from the Institute of Biophysics, Chinese Academy of Science.
In this timely session, top intellectual property attorneys will provide an update on patent law pertaining to personalized medicine issues. You will get a give a brief recap of 35 U.S.C. 101 case law developments followed by an update of the most recent guidance from the US Patent Office on Patent Subject Matter Eligibility. You’ll also receive a survey of international considerations and updates in this important area of patent law, highlighting practical implications of developing 101 case law. You will take away insights into how to adapt a patent strategy in light of these new developments.